We believe in better

We believe medical tests – whether for allergies or disease detection – can be conducted when and where they’re needed. We believe accurate testing can be done quickly, conveniently and less invasively, to improve both the patient and physician experience.

So we’re doing it.

Our leadership team

Moufeed Kaddoura
Founder & CEO

Scientist, Serial entrepreneur Forbes 30under30 – Healthcare

Moufeed Kaddoura
Founder & CEO
Total IgE:
177
Allergies:
Timothy grass, bermuda grass, blue grass, ragweed
Chris Harder, PhD
CTO

Developed 4 diagnostics platforms (device, collection kits and tests) in 13 years. Products approved by FDA, HC, EU, Korea, Singapore and MENA

Chris Harder, PhD
CTO
Total IgE:
1300
Allergies:
Seasonal (ragweed, trees, pollens) and many foods
Bruce Brown
CCO

20 years leading global marketing efforts for global medtech companies, both large international and smaller startup organizations

Bruce Brown
CCO
Total IgE:
150
Allergies:
Horse dander, pollen
Martin Mann, MBA
Director, Regulatory

15+ years of regulatory affairs experience at Phadia, the inventors of the world-leading ImmunoCAP IgE blood tests.

Martin Mann, MBA
Director, Regulatory
Total IgE:
20
Allergies:
None diagnosed
Hemanshu Modi
Vice President, Manufacturing & Quality Operations

20+ years experience in manufacturing and quality operations of medical devices; commercialization of FDA-approved products to international markets

Hemanshu Modi
Vice President, Manufacturing & Quality Operations
Total IgE:
8
Allergies:
None diagnosed

Our investors

Board of Directors

Ruth Abdulmassih
Ruth is the CEO of Path-Tec, a leading provider of specimen collection kits and components. Prior to joining Path-Tec, she held multiple leadership positions at various laboratory and regulated businesses, including 23 years with Abbott. Ruth is a corporate strategist and an experienced business leader.
Dennis Flannelly
Dennis is the Head of Precision Medicine for US Oncology at Merck. Prior to joining Merck, he served as the Vice President and General Manager of Immunodiagnostics at PerkinElmer. Dennis has also served as Global Head of Clinical Marketing for Thermo Fisher Scientific's immunodiagnostics business.
Conrad Seaman
Conrad is the Principal at VeraMito Inc., an investor in Kenota. He brings 15+ years of experience in technology licensing, product management and business development, along with an expertise in banking, software, mobile devices, IoT/IIoT, automotive and manufacturing.